Sirukumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL6 |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6450H9926N1690O1998S46 |
| Molar mass | 144588.95 g·mol−1 |
  (what is this?) (verify) | |
Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[3]
Clinical trials
[edit]Rheumatoid arthritis
[edit]It has started clinical trials.[4] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]
Research
[edit]The drug was previously under development for the treatment of depression.[7]
References
[edit]- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
- ^ Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE (July 2018). "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018". Expert Review of Clinical Immunology. 14 (7): 539–547. doi:10.1080/1744666X.2018.1487291. PMID 29925278. S2CID 49330982.
- ^ a b "Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis". PR News Wire. Cision. 25 May 2011.
- ^ Clinical trial number NCT00718718 for "A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy" at ClinicalTrials.gov
- ^ House DW (16 December 2015). "Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis". Seeking Alpha.
- ^ "IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab". January 2017.
- ^ "Sirukumab - Janssen Biotech". AdisInsight. Springer Nature Switzerland AG.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |